Abstract: The present technology relates to luminescent lanthanide complexes comprising a chelating agent, formed of a macrocycle or ligand, complexing a lanthanide ion Ln3+ selected from terbium and dysprosium, the chelating agent comprising at least one group of the structure (B) below; and a process for detecting a biomolecule using said lanthanide complex comprising coupling a luminescent lanthanide complex of the present technology having a reactive group with said biomolecule.

Abstract: A photopolymerizable composition comprises at least a polymerizable resin, a photosensitizer, an annihilator, and a photoinitiator. The photosensitizer is formulated to absorb an excitation light signal received in a first range of wavelengths. The annihilator is formulated to emit a light signal in a second range of wavelengths different from the first. During the absorption of light by the photosensitizer in the first range of wavelengths, the annihilator emits a light signal in the second range, a photon energy of the emitted light signal being greater than a photon energy of the light signal received by the photosensitizer. The annihilator is also formulated to implement an energy transfer mechanism to excite the photoinitiator for polymerization of the resin. The excited photoinitiator is formulated to generate at least one polymerizable initiator to cause the polymerization reaction. Related methods, such as three-dimensional printing methods, and materials are also disclosed.

Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence comprising successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig? in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig?, said intronic sequence comprising an internal 5? splice site enabling the splicing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3? terminal exon of said gene; B4) a sequence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobu

Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Abstract: Method and system for localizing a region of interest in a medium in which cavitation occurs. Method for localizing a region of interest (R) in a medium (M) in which cavitation occurs, the method comprising the steps consisting in: producing cavitation in the region of interest (R), the cavitation generating an acoustic signal, at each of at least three separate positions, detecting a cavitation signal representative of the acoustic signal of the cavitation, for at least two pairs of cavitation signals, determining a delay between the cavitation signals of each pair of cavitation signals, calculating a localization of the region of interest (R) based on the delays and the positions.

Abstract: This method, for determining the local intensity (I0) of an acoustic field propagating in a target region of a soft solid, at a position located within said target region, includes at least the following steps: determining (102) a value of an ultrasound attenuation coefficient (?) of the soft body in the target region; determining (104) a value of the shear modulus (?) of the soft body in the target region; determining (106) a value of the speed of sound (c) in the target region of the soft body; and building (110), with the values determined in steps a), b) and c), a viscoelastic model (M) of a steady-state displacement induced by an acoustic field having a time invariant shape or a viscoelastic model of a difference between two steady-state displacements induced by an acoustic field having a time invariant shape.

Abstract: Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.

Abstract: Probes for the detection of ?-lactamase-type enzymatic activity. In particular, novel fluorogenic substrates for detecting the presence of a catalytically active ?-lactamase and a detection method using such substrates.

Abstract: A system for the treatment of microorganisms includes: a textile web having optical fibers in warp and/or weft woven with binding threads in warp and/or weft, each of the optical fibers having invasive alterations along the fiber and allowing the emission of light propagating in the fiber at these alterations; a light source arranged opposite one or both free ends of the optical fibers. The textile web includes metallic warp and/or weft threads woven with the binding threads, the metallic threads being based on a metal having a negative effect on the growth of microorganisms. The light source generates a light beam having at least one wavelength in the visible or ultraviolet spectrum.

Abstract: The present invention relates to a dinuclear molybdenum complex with ligands selected from fatty tertiary amines of formula (I): R—N[(CH2)nR2][(CH2)nR3]??(I) wherein R represents a linear or branched alkyl comprising 3 to 30 carbon atoms, preferably 3 to 20, advantageously 7 to 17 carbon atoms; n, identical or different, represents 2 or 3; R2 and R3, identical or different, represent an O, OR, NR?2, COOR?, or COO group, where R?, identical or different, represents a hydrogen atom or an alkaline or alkaline earth metal, preferably R? is H, preferably R2 and R3, identical or different, represent an OH or NH2 group.

Abstract: The invention relates to a method for manufacturing a bio-ink by additive deposition, which comprises supplying: a first solution including between 5 and 40 wt. % gelatin; a second solution including between 15 and 35.wt. % alginate; a third solution including between 1 and 15 wt. % fibrinogen, and optionally living cells in suspension; and creating a mixture including: around 35 to 65 vol. % of the first solution; around 15 to 35 vol. % of the second solution; and around 15 to 35 vol. % of the third solution, said proportions being selected so that they add up to 100%. Said bio-ink allows the additive deposition of objects that can be polymerised by means of a solution including calcium ions and thrombin. Said objects can be incubated and can be used as a substitute for body tissue, for example (with added fibroblasts) as skin substitute.

Abstract: A wearable health and lifestyle device including at least a measurement module configured to be worn by a user in at least a first wearing position, the measurement module comprising a 3-axis accelerometer unit configured to provide acceleration data and inclination data, a temperature measurement unit configured to provide temperature data, a light radiation measurement unit configured to provide light radiation data, said light radiation measurement unit comprising at least one multi-spectral sensor configured to measure wavelength bands over the range 290 nm to 1150 nm, a storage module configured to receive and store said acceleration data, said inclination data, said temperature data and said light radiation data, and an analysis module configured to analyze a data set comprising acceleration data, inclination data, temperature data and light radiation data.

Abstract: An inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus is provided.

Abstract: The invention relates a fluorescent compound of formula I: wherein A is selected from P, P?O and N; ·R1 is a residue comprising an oxygen atom·R2 is a residue comprising an oxygen atom, or a halogen, ·R3, R4 and R5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.

Abstract: The probiotic composition comprises at least one lactic acid bacteria strain, preferably Lactobacillus with intestinal tropism, for use in promoting juvenile growth in livestock, with stimulation of linear growth and/or of IGF-1 level. Exemplary lactic acid bacteria include Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus paracasei and Lactobacillus rhamnosus. The strains can be selected in a mouse model. The invention also relates to a probiotic treatment method using this composition.

Abstract: An in vitro or ex vivo method for determining the ability of an individual to respond to a stimulus, based on the measurement of the expression of at least two different biomarkers, selected from different lists among three lists of biomarkers, from a blood sample of the individual, incubated with the stimulus, as well as tools allowing the implementation of this method and the use of these tools.

Abstract: The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

Abstract: The invention relates to a method for synthesizing ultrasmall silica nanoparticles, useful in particular for diagnostics and/or therapy. More specifically, a method for synthesizing silica nanoparticles, said method comprising the mixing of at least one silane which is negatively charged at physiological pH with at least one silane which is neutral at physiological pH, and/or at least one silane which is positively charged at physiological pH, wherein: —the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0?A?6, —the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0?B?5, —the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 0<C?8. The invention also relates to the obtained ultrasmall silica nanoparticles.

Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.

Abstract: The present invention concerns novel Lactobacillus plantarum strains capable of promoting the growth of a subject, and more particularly the juvenile or prenatal growth of farm animals, and their uses as probiotics.